Skip to main content

Table 5 Multivariable determinants of adhering to medication in the Zoledronate versus Ibandronate Comparative Evaluation (ZICE) trial

From: The use of randomisation-based efficacy estimators in non-inferiority trials

Purpose Variable Adjusted odds ratio 95% confidence interval p value
Lower Upper
Associated with the development of a SRE within 12 months Gender (female compared to male) 1.29 0.36 4.55 0.697
18.5 kg/m2 < BMI ≤ 25 kg/m2 (normal/healthy weight) compared to ≤ 18.5 kg/m2 (underweight) 2.19 0.74 6.47 <0.001
25 kg/m2 < BMI ≤ 30 kg/m2 (overweight) compared to ≤ 18.5 kg/m2 (underweight) 2.05 0.70 6.00
30 kg/m2 < BMI ≤ 35 kg/m2 (moderately obese) compared to ≤ 18.5 kg/m2 (underweight) 2.35 0.79 7.03
35 kg/m2 < BMI ≤ 40 kg/m2 (severely obese) compared to ≤ 18.5 kg/m2 (underweight) 3.07 0.95 9.95
BMI > 40 kg/m2 (very severely obese) compared to ≤ 18.5 kg/m2 (underweight) 3.90 1.06 14.31
QLQ-C30 global health domain (per unit increase) 1.00 1.00 1.01 0.358
QLQ-C30 role functioning domain (per unit increase) 1.00 1.00 1.01 0.300
QLQ-C30 nausea/vomiting domain (per unit increase) 1.01 1.01 1.02 0.000
QLQ-C30 dyspnoea domain (per unit increase) 1.00 0.99 1.00 0.547
SRE within the 3 months prior to baseline compared to no SRE within 3 months prior to baseline 1.07 0.79 1.46 0.660
Recent use of pain medication at baseline compared to no recent use of pain medication 0.65 0.45 0.94 0.021
Differentially associated with adherence by trial arm Orally administered ibandronic acid arm (main effect) 5.77 2.05 16.26 0.001
QLQ-C30 cognitive functioning (main effect) 1.01 1.00 1.02 0.005
Orally administered ibandronic acid arm x QLQ-C30 cognitive functioning (interaction) 0.99 0.98 1.00 0.061
Use of chemotherapy at baseline (main effect) 2.12 1.28 3.53 0.004
Orally administered ibandronic acid arm x Use of chemotherapy at baseline (interaction) 0.47 0.22 1.02 0.057